Almudena Moreno-Borrallo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Almudena Moreno-Borrallo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Andrew Harkin
1 shared publicationAyushi Jain
1 shared publicationBianca Dumontel
1 shared publicationBinh Thanh Mai
1 shared publicationCarla Jiménez-Jiménez
1 shared publication- Eduardo Ruiz-Hernandez
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, D02 YY50 Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Elsevier in Materials Today Advances
- Vol. 31
Stimuli-responsive polymeric nanoparticles and nanocomposites for targeted glioblastoma therapy and diagnosis: recent preclinical progress and translational challenges
- 7 August 2026
- Published by Elsevier in Materials Today Advances
- Vol. 31
Open AccessStimuli-responsive polymeric nanoparticles and nanocomposites for targeted glioblastoma therapy and diagnosis: recent preclinical progress and translational challenges
- Open Access
- 5 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Sustainability
- Vol. 4 (8) , 3208-3214
Young Chemists for Change – a perspective from Ireland on EDI’s impact for a sustainable future
This Forum article evaluates the impact and gathers insights from the 2024 Young Chemists for Change (YCFC) conference, an equality, diversity and inclusion (EDI)-centred event for early-career chemists in Ireland and the UK.
- 5 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Sustainability
- Vol. 4 (8) , 3208-3214
Open AccessYoung Chemists for Change – a perspective from Ireland on EDI’s impact for a sustainable future
This Forum article evaluates the impact and gathers insights from the 2024 Young Chemists for Change (YCFC) conference, an equality, diversity and inclusion (EDI)-centred event for early-career chemists in Ireland and the UK.
- Open Access
- 2 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5344
Do We Know Enough About the Safety Profile of Silver Nanoparticles in Oncology? A Focus on Novel Methods and Approaches
Silver nanoparticles (AgNPs) have emerged as promising agents in cancer diagnostics and/or therapy, demonstrating a lot of possible pharmacological actions. However, understanding the pharmacokinetics and safety profiles of nanoparticles, which is crucial for their clinical application, still raises many questions. Studies indicate that AgNPs can accumulate in tumour tissues, improving drug delivery and specificity. However, their interaction with biological systems necessitates thorough safety evaluations. Classical methods for assessing AgNPs’ safety include cytotoxicity assays, genotoxicity tests, and histopathological examinations. However, novel techniques are emerging, such as advanced imaging and biomarker analysis, offering more precise toxicity assessments. Prediction models, including computational simulations and in silico analyses, are being developed to forecast AgNPs’ toxicity profiles. These models aim to reduce reliance on animal testing and expedite the evaluation process. To mitigate potential risks associated with nanoparticle-based therapies, strategies such as surface modification, controlled release systems, and targeted delivery are being explored. These methods aim to enhance therapeutic efficacy while minimizing adverse effects. The main aim of this review article is to describe AgNPs from the point of view of their pharmacokinetic/toxicokinetic profile in the light of modern knowledge. Special attention will be given to novel methods for assessing the safety and toxicity profiles of AgNPs, providing insights into their interactions with cancer therapies and their potential clinical applications.
- 2 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5344
Open AccessDo We Know Enough About the Safety Profile of Silver Nanoparticles in Oncology? A Focus on Novel Methods and Approaches
Silver nanoparticles (AgNPs) have emerged as promising agents in cancer diagnostics and/or therapy, demonstrating a lot of possible pharmacological actions. However, understanding the pharmacokinetics and safety profiles of nanoparticles, which is crucial for their clinical application, still raises many questions. Studies indicate that AgNPs can accumulate in tumour tissues, improving drug delivery and specificity. However, their interaction with biological systems necessitates thorough safety evaluations. Classical methods for assessing AgNPs’ safety include cytotoxicity assays, genotoxicity tests, and histopathological examinations. However, novel techniques are emerging, such as advanced imaging and biomarker analysis, offering more precise toxicity assessments. Prediction models, including computational simulations and in silico analyses, are being developed to forecast AgNPs’ toxicity profiles. These models aim to reduce reliance on animal testing and expedite the evaluation process. To mitigate potential risks associated with nanoparticle-based therapies, strategies such as surface modification, controlled release systems, and targeted delivery are being explored. These methods aim to enhance therapeutic efficacy while minimizing adverse effects. The main aim of this review article is to describe AgNPs from the point of view of their pharmacokinetic/toxicokinetic profile in the light of modern knowledge. Special attention will be given to novel methods for assessing the safety and toxicity profiles of AgNPs, providing insights into their interactions with cancer therapies and their potential clinical applications.
- Open Access
- 5 December 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 157, 395-407
Biomimetic camouflaged nanoparticles with selective cellular internalization and migration competences
- 5 December 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 157, 395-407
Open AccessBiomimetic camouflaged nanoparticles with selective cellular internalization and migration competences